In Pursuit of the Ideal Antipsychotic: "Goldilocks" Actions
Psychosis occurs when too much dopamine exists in the synapses, and the action, akin to Goldilocks's first bowl of soup, is "too hot." Every antipsychotic that reduces the positive symptoms of psychosis such as delusions and hallucinations does so by blocking dopamine D 2 receptors, most likely those of the mesolimbic dopamine pathway. 1 Unfortunately, the blocking is often nonspecific, which is typical of conventional antipsychotic actions. Thus, when D 2 receptors in the nigrostriatal dopamine pathway are also blocked, a penalty is paid in motor side effects, namely extrapyramidal reactions, pseudoparkinsonism, and ultimately, tardive dyskinesia. The blocking causes levels that are too low or "too cold" (like Goldilocks's second bowl of soup).
parts of the brain where the concentration is too high yet permitting normal dopamine activity in other parts of the brain. The presynaptic D 2 receptors responsible for regulating dopamine release are less sensitive in detecting dopamine than are postsynaptic D 2 receptors, so physiologic neurotransmission continues until dopamine levels build up sufficiently to stimulate the presynaptic D 2 receptors, thereby turning off further dopamine release.
In the brain, regional differences may occur in the activity of dopamine neurons and the sensitivity of various presynaptic and postsynaptic D 2 receptors to dopamine, especially during disease states and as a consequence of various drug treatments. The concept of dopamine system stabilization is based on preserving or enhancing dopaminergic neurotransmission where it is low ("too cold") and reducing dopaminergic neurotransmission where it is too high ("too hot"). In terms of treating psychosis, the goal is to reduce hyperactive dopamine neurons that mediate psychosis and at the same time enhance underactive dopamine neurons that mediate negative and cognitive symptoms (mesocortical pathway) while preserving physiologic function in dopamine neurons that regulate motor movement and prolactin-all in the same brain at the same time.
Ever since the motor complications of conventional antipsychotics were recognized, attempts have been made to preserve their therapeutic effects but reduce their motor side effectsaiming for a synaptic soup that is "just right." One approach has been to reduce psychotic symptoms with a mechanism other than blocking D 2 receptors, but these attempts have been unsuccessful to date. The successful approach has been the one that changes the way a drug binds to D 2 receptors, creating that "just right" combination of antipsychotic effects without motor side effects. Not only do the atypical antipsychotics achieve this goal, but so may a new generation of agents, and by a novel mechanism called dopamine system stabilization.
What is dopamine system stabilization?
A new concept for the action of antipsychotic drugs that do not induce motor side effects is dopamine system stabilization.
2-9 The brain normally stabilizes dopamine neurotransmission by attaining a balance between presynaptic and postsynaptic D 2 receptor stimulation. These 2 mechanisms act together: presynaptic dopamine receptors are stimulated, and dopamine release at specific postsynaptic sites is turned off, thus reducing excessive dopamine activation in 
How does a drug stabilize dopamine?
When dopamine is dysregulated in psychoses (e.g., schizophrenia), dopamine system stabilizers (DSSs), which bind to D 2 receptors in a manner that can be either stimulating or antagonizing, are helpful. 3 These stabilizers are far different from receptor antagonists, which always block the action of dopamine completely and reduce output from D 2 receptors ("too cold"), and very different from dopamine itself, which is a full agonist at D 2 receptors that creates maximum action (if the amount is high enough), making the receptors "too hot." DSSs, on the other hand, theoretically create the desired dopamine balance. Thus, when dopamine activity is too cold, a DSS increases dopamine output, but to a level not as hot as real dopamine. In the presence of maximum dopamine, DSSs reduce the amount until it is "just right."
Pharmacologically, this mechanism is known as partial agonist action, which means activation at low dopaminergic tone and inhibition at high dopaminergic tone, thus stabilizing dopamine output from either direction.
10,11 Molecularly, the exact mechanism of partial agonist binding to D 2 receptors remains somewhat obscure but is hypothesized to exploit differences in D 2 receptors presynaptically vs. postsynaptically, in various brain regions, or in their affinities, distribution, density, and tightness of coupling to a physiologic output.
Clinically, the term partial agonist may be misinterpreted because "partial" can imply weak or incomplete. DSSs, however, are not less effective than other types of antipsychotics. The prototypical member of this class, tion, one can achieve an antipsychotic action without motor side effects. Early clinical development of several DSSs is ongoing or imminent, and testing of aripiprazole is in late stages.
Summary
Dopamine system stabilizers are a potential new class of antipsychotic agents without motor side effects. All known effective antipsychotics act at D 2 receptors. A novel concept for an antipsychotic without motor side effects is to stabilize these receptors rather than block them harshly.
